Clinical Trials Sponsored by Vertex Pharmaceuticals Incorporated

Total 287 results

Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Healthy Participants
Vertex Pharmaceuticals Incorporated
Tibotec BVBA

Completed

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Hepatitis C | Opioid-Related Disorders

United States
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Hepatitis C
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Moldova, Republic of, Romania, France
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) (KONDUCT)

Cystic Fibrosis

United States, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United Kingdom, United States, Canada
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Moldova, Republic of
Alios Biopharma Inc.
Vertex Pharmaceuticals Incorporated

Terminated

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Australia, New Zealand
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United States
University of Florida
Vertex Pharmaceuticals Incorporated

Completed

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (STEADFAST)

Hepatitis C, Chronic

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)

Cystic Fibrosis

United States, France, Belgium, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Orkambi Treatment in 2 to 5 Year Old Children With CF

Cystic Fibrosis

United States
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Hepatitis C

Japan
Vertex Pharmaceuticals Incorporated
National Cancer Institute (NCI)

Withdrawn

A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors

Refractory Solid Tumors

United States
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

Cystic Fibrosis

United States
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Energy Balance and Weight Gain With Ivacaftor Treatment

Cystic Fibrosis

United States
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Medical University of South Carolina
Vertex Pharmaceuticals Incorporated

Completed

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Cystic Fibrosis
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated

Completed

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Hepatitis C
Karolinska University Hospital
Hadassah Medical Organization; Vertex Pharmaceuticals Incorporated

Unknown

Gastrointestinal Study at Orkambi Therapy in CF Patients

Cystic Fibrosis

Sweden
Vertex Pharmaceuticals Incorporated
Duke Clinical Research Institute; ViroChem Pharma

Completed

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

HCV Infection

Puerto Rico, United States, Canada
University Medical Center Groningen
Vertex Pharmaceuticals Incorporated; Marien Hospital Wesel

Completed

Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function (ROOTS)

Cystic Fibrosis in Children

Netherlands, Germany
Nottingham University Hospitals NHS Trust
Manchester Metropolitan University; Vertex Pharmaceuticals Incorporated

Completed

Gut Imaging for Function & Transit in CF - GIFT-CF 3 (GIFT-CF3)

Cystic Fibrosis

United Kingdom
Universitaire Ziekenhuizen KU Leuven
KU Leuven; Vertex Pharmaceuticals Incorporated; University of Lisbon

Withdrawn

Organoid Study R334W

Cystic Fibrosis

Spain, Italy, France, Belgium, Portugal
Institut de Recherches Cliniques de Montreal
Vertex Pharmaceuticals Incorporated; Université de Montréal

Completed

Simplification of CF-related Diabetes Screening at Home (AtHome)

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

Canada
Sound Pharmaceuticals, Incorporated

Active, not recruiting

SPI-1005 for the Treatment of Meniere's Disease (STOPMD-3)

Meniere Disease | Ménière

United States
Sound Pharmaceuticals, Incorporated

Enrolling by invitation

SPI-1005 Treatment in Severe COVID-19 Patients

Coronavirus Infection | Covid19 | Corona Virus Infection | Coronavirus

United States
Sound Pharmaceuticals, Incorporated

Completed

SPI-1005 for the Treatment of Patients With Meniere's Disease

Meniere's Disease

United States
Sound Pharmaceuticals, Incorporated

Unknown

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)

Noise Induced Hearing Loss

United States
Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Cancer | Hearing Loss

United States
Acetylon Pharmaceuticals Incorporated

Completed

Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects

Healthy

United States
Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Meniere's Disease

United States
Salient Pharmaceuticals Incorporated

Unknown

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Diarrhea | Medullary Thyroid Cancer

United States
Pneuma Pharmaceuticals Incorporated

Terminated

Calfactant for Direct Acute Respiratory Distress Syndrome (CARDS)

Respiratory Distress Syndrome, Adult

Korea, Republic of, United States, Canada, New Zealand, Australia, Israel

Clinical Trials Sponsored by Vertex Pharmaceuticals Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations